Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21117295 | 0.95 | ESR2 (0.50) | ESR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL25884467 | 0.94 | ESR2 (0.49) | ESR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13267179 | 0.93 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL18078978 | 0.87 | ACR (0.46) | ESR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL27267183 | 0.86 | SMN1; SMN2 (0.53) | ESR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL30720642 | 0.86 | SMN1; SMN2 (0.53) | ESR2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL16684739 | 0.86 | HDAC8 (0.61) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL12488363 | 0.86 | HDAC1 (0.56) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL21288239 | 0.85 | CA1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL38657721 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307797-B1 | ALIGNMENT POLYMERS | TRANSITIONS OPTICAL INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11130912-B2 | Alignment polymers | TRANSITIONS OPTICAL, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10875833-B2 | Alignment compounds | TRANSITIONS OPTICAL, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3307798-B1 | ALIGNMENT COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10619098-B2 | Ultraviolet light absorbers | TRANSITIONS OPTICAL, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3201292-B1 | ULTRAVIOLET LIGHT ABSORBERS | TRANSITIONS OPTICAL INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180127653-A1 | Alignment Polymers | TRANSITIONS OPTICAL, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127653-A1 | Alignment Polymers | TRANSITIONS OPTICAL, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180086725-A1 | Alignment Compounds | TRANSITIONS OPTICAL, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086725-A1 | Alignment Compounds | TRANSITIONS OPTICAL, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20120002141-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120002141-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003401-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7838089-B2 | with biphenylcyclohexane-based skeleton; nematic at room temperature, improved response; paraelectric | SONY CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090168009-A1 | with biphenylcyclohexane-based skeleton; nematic at room temperature, improved response; paraelectric | SONY CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1739151-A1 | Mesogenic compounds, liquid crystal medium and liquid display | MERCK PATENT GmbH (DE) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10619098-B2 | Ultraviolet light absorbers | ERCC1, MCM4, ERCC4 | ESR2 1035/4885ALDH1A1 590/4885KDM4E 1669/4885 |
| US-20120003401-A1 | MESOGENIC STABILIZERS | PYM1, BMI1, C1S | ESR2 2073/4885ALDH1A1 3077/4885KDM4E 720/4885 |
| US-10875833-B2 | Alignment compounds | CYP19A1, ESR1, CCNE2 | ESR2 44/4885ALDH1A1 955/4885KDM4E 811/4885 |
| US-20120002141-A1 | MESOGENIC STABILIZERS | BMI1, METTL14, PYM1 | ESR2 3153/4885ALDH1A1 3066/4885KDM4E 376/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | ESR2 1851/4885ALDH1A1 2978/4885KDM4E 3764/4885 |
| US-20180086725-A1 | Alignment Compounds | CYP19A1, ESR1, CCNE2 | ESR2 44/4885ALDH1A1 955/4885KDM4E 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.